Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first “real-life” experience in primary gastroenterology centers in Italy

BACKGROUND: Adalimumab (ADA) is the key treatment for ulcerative colitis (UC) unresponsive or intolerant to standard treatments. Our aim was to assess the efficacy and safety of ADA in treating ambulatory UC patients in primary gastroenterology centers. METHODS: Fifteen patients (6 male, median age...

Descripción completa

Detalles Bibliográficos
Autores principales: Tursi, Antonio, Elisei, Walter, Picchio, Marcello, Penna, Antonio, Forti, Giacomo, Giorgetti, Gian Marco, Faggiani, Roberto, Zampaletta, Costantino, Pelecca, Giorgio, Brandimarte, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188935/
https://www.ncbi.nlm.nih.gov/pubmed/25331091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188935/
https://www.ncbi.nlm.nih.gov/pubmed/25331091

Ejemplares similares